Immatics Builds on Genedata Innovation
Immatics Builds on Genedata Innovation
4 Pages© Immatics INDUSTRY Cell & Gene Therapy (CGT) GENEDATA CUSTOMER SINCE 2019 ABOUT IMMATICS Immatics is a globally operating clinical-stage biopharmaceutical company developing novel T cell receptor (TCR) -based immunotherapies KEY CHALLENGES Need a purpose-built enterprise software solution to increase efficiency of proprietary TCR engineering for cell and gene therapy R&D RESULTS Streamlined workflows, central access to all TCR- related R&D data, improved collaboration across various teams, more transparent decision-making GENEDATA SOLUTION Biotechnology – Cell & Gene Therapy (CGT) Background & Challenges Immatics is focusing on the development of novel therapies to treat cancer patients with solid tumors. To develop T cell receptor-based immunotherapies, Immatics employs t
